4-吡啶基硫代乙S-酸 | 765844-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-吡啶基硫代乙S-酸
• 英文名称: 4-pyridinylthioacetic acid
• 英文别名: 4-pyridylthioacetic acid；pyridin-4-ylthioacetic acid；(Pyridin-4-yl)ethanethioic S-acid；2-pyridin-4-ylethanethioic S-acid
• CAS: 765844-51-7
• 化学式: C₇H₇NOS
• mdl: MFCD11615778
• 分子量: 153.205
• InChiKey: CVESUUBVBNKUTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-吡啶基硫代乙S-酸 、 5,5'-sulfonylbis(1H-indene-1,3(2H)-dione) 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 0.17h， 以62%的产率得到5-({1,3-dioxo-2-[2-(pyridin-4-ylsulfanyl)acetyl]-2,3-dihydro-1H-inden-5-yl}sulfonyl)-2-[2-(pyridin-4-ylsulfanyl)acetyl]-2,3-dihydro-1H-indene-1,3-dione bissodium salt
  参考文献：
  名称：

  [EN] SMALL MOLECULE ANTAGONISTS OF PF4
  [FR] ANTAGONISTES À PETITES MOLÉCULES DE PF4

  摘要：

  本申请提供了式（I）的化合物或其药学上可接受的盐，其中Y，R1，R2，R3和R4如本文所述。还公开了使用这些化合物抑制PF4四聚体化和治疗相关疾病和状况的方法，例如肝素诱导的血小板减少和血栓形成（HITT）和疫苗诱导的免疫性血栓性血小板减少症（VITT），制备这些化合物的方法以及含有这些化合物的制药组合物。

  公开号：

  WO2022073003A1
• 作为产物：
  描述：

  1-(4-吗啉基)-2-(4-吡啶基)乙硫酮 在 sodium hydroxide 作用下， 反应 0.02h， 生成 4-吡啶基硫代乙S-酸
  参考文献：
  名称：

  Moghaddam, Firouz Matloubi; Ghaffarzadeh, Mohammad; Dakamin, Mohammad G., Journal of Chemical Research - Part S, 2000, # 5, p. 228 - 229

  摘要：

  DOI：

文献信息

• [EN] THE PRESENT INVENTION RELATES TO THE NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9A-AZA­9A-HOMOERYTHROMYCIN A 9A,11-CYCLIC CARBAMATES<br/>[FR] NOUVEAUX DERIVES 3-DECLADINOSYL DE CARBAMATES 9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCINE A 9A,11-CYCLIQUES
  申请人：PLIVA D D

  公开号：WO2004029067A1

  公开（公告）日：2004-04-08

  The present invention relates to the new 3-decladinosyl derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A 9a,11-cyclic carbamate of the general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein R1 individually stands for hydrogen, hydroxyl or a group of the formula (II), wherein X individually stands for C1-C6alkyl group, C2-C6alkenyl group or X individually stands for C1-C6alkyl group with at least one incorporated O, S or N atom or X individually stands for (CH2)n-Ar or X individually stands for (CH2)n-heterocycloalkyl, wherein (CH2)n individually stands for alkyl, wherein n is 1-10, with or without incorporated atom O, S or N, wherein Ar individually stands for 5-10-membered monocyclic or bycyclic aromatic ring with 0-3 atom O, S or N, unsubstituted or substituted with 1-3 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino--C1-C3alkyl or amino-C1-C3dialkyl, CN, SO2NH2, C1-C3alkyl, and heterocycloalkyl stands for unaromatic, partially or completely saturated 3-10-membered monocyclic or bicyclic ring system, which includes 3-8-membered monocyclic or bicyclic ring, which includes 6-membered aromatic or heteroaromatic ring connected with a unaromatic ring with or without incorporated O, S or N atom, unsubstituted or substituted with 1-4 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino--C1-C3alkyl or amino-Cl-C3dialkyl, CN, SO2NH2, C1-C3alkil, -C(O)-, COOH or R1 together with R2 stands for ketone, R2 individually stands for hydrogen or together with R1 stands for ketone or together with R3 stands for ether, R3 individually stands for hydroxyl, a group of the formula -OX or together with R2 stands for ether, R4 individually stands for hydrogen, C1-C4alkyl group or C2-C4alkenyl group, and R5 individually stands for hydrogen or hydroxyl protected group, to intermediates for synthesis of other macrolide compounds with antibacterial activity, to the proces for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to the process for the preparation of pharmaceutical compositions, as well as the use of pharmaceutical compositions for treating bacterial infections.

  本发明涉及新的9-去氧-9a-氮杂-9a-同蚓霉素A 9a,11-环氨基甲酸酯的3-脱氯基衍生物的一般式(I)，它们与无机或有机酸的药学上可接受的加合物盐以及它们的水合物，其中R1分别代表氢、羟基或式(II)的基团，其中X分别代表C1-C6烷基基团、C2-C6烯基基团或X分别代表至少含有一个O、S或N原子的C1-C6烷基基团，或者X分别代表(CH2)n-Ar或X分别代表(CH2)n-杂环烷基，其中(CH2)n分别代表烷基，n为1-10，或有或无含有原子O、S或N，其中Ar分别代表含有0-3个原子O、S或N的5-10元单环或双环芳香环，未取代或取代1-3个基团，这些基团独立选择自卤素、羟基、OMe、NO2、NH2、氨基-C1-C3烷基或氨基-C1-C3二烷基、CN、SO2NH2、C1-C3烷基，而杂环烷基代表非芳香、部分或完全饱和的3-10元单环或双环环系，其中包括3-8元单环或双环环，其中包括与不含有或含有1-4个基团的未取代或取代6元芳香或杂芳香环相连接的非芳香环，这些基团独立选择自卤素、羟基、OMe、NO2、NH2、氨基-C1-C3烷基或氨基-C1-C3二烷基、CN、SO2NH2、C1-C3烷基、-C(O)-、COOH或R1与R2一起代表酮，R2分别代表氢，或与R1一起代表酮，或与R3一起代表醚，R3分别代表羟基、-OX的基团或与R2一起代表醚，R4分别代表氢、C1-C4烷基或C2-C4烯基，R5分别代表氢或羟基保护基团，用于合成具有抗菌活性的其他大环内酯化合物的中间体，用于它们的制备过程，用于它们与无机或有机酸的药学上可接受的加合物盐以及它们的水合物，用于制备药物组合物的制备过程，以及用于治疗细菌感染的药物组合物的使用。
• Diaminopropionic acid derivatives
  申请人：Fotouhi Nader

  公开号：US20050080119A1

  公开（公告）日：2005-04-14

  A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

  一种用于治疗再灌注损伤的化合物，其化学式为1a，以及其盐、前药和相关化合物。
• Process for the preparation of substituted or unsubstituted
  申请人：Oce-Andeno B.V.

  公开号：US03966741A1

  公开（公告）日：1976-06-29

  4-Pyridylthioacetic acid is prepared economically without the formation of any noxious substance by (1) reacting a 4-nitropyridyl-N-oxide with a lower alkyl thioglycolate or with thioglycolic acid to form 4-thioglycolic acid (or 4-thioglycolate)-pyridyl-N-oxide, (2) reducing the latter oxide in the form of its 4-alkyl thioglycolate to obtain the corresponding 4-pyridylthioglycolic acid ester, and (3) converting said ester into a 4-pyridylthioacetic acid by saponification followed by acidification. When a lower alkyl thioglycolate is used for the reaction in step (1), step (2) can follow directly for reduction of the reaction product, and high yields are obtained.

  4-吡啶硫乙酸可以通过以下方法经济实惠地制备，而且不会形成任何有害物质：(1) 用较低的烷基硫代乙酸酯或硫代乙酸与4-硝基吡啶-N-氧化物反应，形成4-硫代乙酸（或4-硫代乙酸酯）-吡啶-N-氧化物，(2) 以其4-烷基硫代乙酸酯的形式还原该氧化物，得到相应的4-吡啶硫乙酸酯，(3) 通过皂化和酸化将该酯转化为4-吡啶硫乙酸。当使用较低的烷基硫代乙酸酯进行第一步反应时，可以直接进行第二步还原反应，从而得到高收率。
• Morpholine Compound
  申请人：Tanaka Yoshihito

  公开号：US20070265257A1

  公开（公告）日：2007-11-15

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  化合物的化学式为(1)，其中环A是芳基，可选地具有取代基等；环B是芳烃，可选地具有取代基等；m=0-2；n=1-5；X是键等；Y是键等；Z是氢原子等或其药学上可接受的盐，其水合物或溶剂化物具有对CCR3的亲和力，并可用于治疗和/或预防免疫或炎症性疾病的药物产品。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20090099205A1

  公开（公告）日：2009-04-16

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。